litlas
Log inCreate account

Alain Ravaud

Active 1990–2024

114
Papers
38,835
Citations
79
h-index
113
i10-index

Citations

Citations per year for Alain Ravaud1994: 1 citations1995: 1 citations1997: 3 citations1998: 3 citations1999: 14 citations2000: 22 citations2001: 25 citations2002: 45 citations2003: 48 citations2004: 41 citations2005: 53 citations2006: 67 citations2007: 86 citations2008: 110 citations2009: 174 citations2010: 201 citations2011: 219 citations2012: 200 citations2013: 230 citations2014: 166 citations2015: 162 citations2016: 306 citations2017: 367 citations2018: 500 citations2019: 1,694 citations2020: 2,017 citations2021: 1,708 citations2022: 1,231 citations2023: 896 citations2024: 1,360 citations2025: 558 citations2026: 14 citations1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,942 citing papers, 24% of this breakdownChina: 1,616 citing papers, 9.8% of this breakdownFrance: 1,102 citing papers, 6.7% of this breakdownItaly: 1,001 citing papers, 6.1% of this breakdownUnited Kingdom: 952 citing papers, 5.8% of this breakdownGermany: 739 citing papers, 4.5% of this breakdownJapan: 705 citing papers, 4.3% of this breakdownCanada: 650 citing papers, 3.9% of this breakdownSpain: 622 citing papers, 3.8% of this breakdownNetherlands: 450 citing papers, 2.7% of this breakdownAustralia: 400 citing papers, 2.4% of this breakdownSwitzerland: 382 citing papers, 2.3% of this breakdown
0%24%Other 23.7%

Institutions

Fields

  • Medicine77.2%
  • Biochemistry, Genetics and Molecular Biology12.8%
  • Immunology and Microbiology4%
  • Neuroscience3.9%
  • Engineering0.5%
  • Mathematics0.3%
  • Other1.3%

Topics

  • Cancer Immunotherapy and Biomarkers14%
  • Renal cell carcinoma treatment8.2%
  • Bladder and Urothelial Cancer Treatments4.9%
  • Ferroptosis and cancer prognosis3.3%
  • Immunotherapy and Immune Responses3.2%
  • CAR-T cell therapy research2.7%
  • Other63.7%

Coauthors

All papers

Open in search
  1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 cited by 4,643

  2. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma - New England Journal of Medicine 2015 cited by 5,890

  3. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    Authors: David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles - Nature Medicine 2018 cited by 1,250

  4. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Tom Powles, Joaquim Bellmunt, Éva Compérat, Maria De Santis, Robert Huddart, Yohann Loriot, Andrea Necchi, Begoña P. Valderrama, Alain Ravaud, Shahrokh F. Shariat, Bernadett Szabados, Michiel S. van der Heijden, Silke Gillessen - Annals of Oncology 2021 cited by 525

  5. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Authors: Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee, Robert D. Hawkins, Alain Ravaud, B. Yа. Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K. Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer - The Lancet 2019 cited by 1,010

  6. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

    Authors: Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, Yohann Loriot, Nicholas J. Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta Retz, Daniel Castellano, Aristotelis Bamias, Aude Fléchon, Gwénaëlle Gravis, Syed A. Hussain, Toshimi Takano, Ning Leng, Edward E. Kadel, Romain Banchereau, Priti S. Hegde, Sanjeev Mariathasan, Na Cui, Xiaodong Shen, Christina Louise Derleth, Marjorie C. Green, Alain Ravaud - The Lancet 2017 cited by 1,416

  7. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

    Authors: Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Bernadett Szabados, Albert Font Pous, Gwénaëlle Gravis, Urbano Anido, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Pieter‐Jan van Dam, Diana Stanoeva, Sofie Daelemans, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano - Nature Medicine 2019 cited by 571

  8. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    Authors: Shubham Pant, Martin Schüler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Toshihiko Doi, Josep Tabernero, David A. Reardon, Christophe Massard, Anna Minchom, Iwona Ługowska, Omar Carranza, Dirk Arnold, Martin Gutierrez, Helen Winter, Kim Stuyckens, Lauren Crow, Saltanat Najmi, Constance Hammond, Shibu Thomas, Ademi Santiago-Walker, Spyros Triantos, Hussein Sweiti, Yohann Loriot, Omar Carranza, Martin Alberto Greco, Omar Carranza, Anthony M. Joshua, Christos S. Karapetis, Christopher D. Hart, Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang and 33 more - The Lancet Oncology 2023 cited by 200

  9. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    Authors: Bernadett Szabados, Mark Kockx, Zoe J. Assaf, Pieter‐Jan van Dam, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Albert Font Pous, Gwénaëlle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles - European Urology 2022 cited by 190

  10. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

    Authors: Arnaud Méjean, Alain Ravaud, Simon Thézenas, Sandra Colas, Jean‐Baptiste Beauval, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Hervé Lang, Laurent Guy, Gwénaëlle Gravis, Frédéric Rolland, Claude Linassier, É. Lechevallier, Christian Beisland, Michael Aitchison, Stéphane Oudard, Jean‐Jacques Patard, C Théodore, Christine Chevreau, Brigitte Laguerre, Jacques Hubert, Marine Gross‐Goupil, Jean‐Christophe Bernhard, Laurence Albigès, Marc‐Olivier Timsit, Thierry Lebrét, Bernard Escudier - New England Journal of Medicine 2018 cited by 940

  11. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Authors: Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud - The Lancet 2008 cited by 3,012

  12. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

    Authors: Thomas Powles, Joaquim Bellmunt, Éva Compérat, Maria De Santis, Robert Huddart, Yohann Loriot, Andrea Necchi, Begoña P. Valderrama, Alain Ravaud, Shahrokh F. Shariat, Bernadett Szabados, Michiel S. van der Heijden, Silke Gillessen - Annals of Oncology 2024 cited by 159

  13. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

    Authors: Gwénaëlle Gravis, Karim Fizazi, Florence Joly, Stéphane Oudard, Franck Priou, Benjamin Esterni, I. Latorzeff, R. Delva, I. Krakowski, Brigitte Laguerre, Frédéric Rolland, Christine Théodore, G. Deplanque, Jean Marc Ferrero, Damien Pouessel, Loı̈c Mourey, Philippe Beuzeboc, Sylvie Zanetta, Muriel Habibian, Jean François Berdah, Jérôme Dauba, Marjorie Baciuchka, Christian Platini, Claude Linassier, Jean-Luc Labourey, Jean Pascal Machiels, Claude El Kouri, Alain Ravaud, Etienne Suc, Jean Christophe Eymard, Ali Hasbini, Guilhem Bousquet, M. Soulié - The Lancet Oncology 2013 cited by 740

  14. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

    Authors: Alain Ravaud, Robert J. Motzer, Hardev Pandha, Daniel J. George, Allan J. Pantuck, Anup Patel, Yen‐Hwa Chang, Bernard Escudier, Frede Donskov, Ahmed Magheli, Giacomo Cartenì, Brigitte Laguerre, Piotr Tomczak, J. Breza, Paola Gerletti, Mariajosé Lechuga, Xun Lin, Jean‐François Martini, Krishnan Ramaswamy, Michelle Casey, Michael Staehler, Jean‐Jacques Patard - New England Journal of Medicine 2016 cited by 777

  15. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Authors: Manish R. Patel, John Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Carolyn D. Britten, Luc Dirix, Keun‐Wook Lee, Mathew Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Arnold B. Gelb, Junyuan Xiong, Galit Rosen, James L. Gulley, Andrea B. Apolo - The Lancet Oncology 2017 cited by 588

  16. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

    Authors: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean‐Christophe Pignon, Miriam Ficial, Osvaldo Arén Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthélémy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jerónimo Rafael Rodríguez‐Cid, Sumanta K. Pal, André M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, Brian I. Rini - Clinical Cancer Research 2020 cited by 242

  17. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study

    Authors: Marie Kostine, L. Rouxel, Thomas Barnetche, Rémi Veillon, Florent Martin, Caroline Dutriaux, L. Dousset, Anne Pham‐Ledard, S. Prey, M. Beylot‐Barry, Amaury Daste, Marine Gross‐Goupil, Julie Lallier, Alain Ravaud, Édouard Forcade, B Bannwarth, Marie‐Elise Truchetet, Christophe Richez, Nadia Mehsen, Thierry Schaeverbeke - Annals of the Rheumatic Diseases 2017 cited by 302

  18. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

    Authors: Marie Kostine, Eleonora Mauric, Alice Tison, Thomas Barnetche, Aurélien Barré, Macha Nikolski, L. Rouxel, Caroline Dutriaux, L. Dousset, S. Prey, M. Beylot‐Barry, Julien Sénéschal, Rémi Veillon, Charlotte Vergnenègre, Amaury Daste, Charlotte Domblides, Baptiste Sionneau, Marine Gross‐Goupil, Alain Ravaud, Édouard Forcade, Thierry Schaeverbeke - European Journal of Cancer 2021 cited by 93

  19. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

    Authors: Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolás Isambert, Edward F. McClay, Ahmad Awada, Christian Borel, Laureen S. Ojalvo, Christoph Helwig, P. Alexander Rolfe, James L. Gulley, Nicolas Penel - Journal for ImmunoTherapy of Cancer 2020 cited by 82

  20. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

    Authors: Arnaud Méjean, Alain Ravaud, Simon Thézenas, Christine Chevreau, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Hervé Lang, Laurent Guy, Gwénaëlle Gravis, Frédéric Rolland, Claude Linassier, É. Lechevallier, Stéphane Oudard, Brigitte Laguerre, Marine Gross‐Goupil, Jean‐Christophe Bernhard, Sandra Colas, Laurence Albigès, Thierry Lebrét, Jean‐Marc Tréluyer, Marc‐Olivier Timsit, Bernard Escudier - European Urology 2021 cited by 128

  21. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

    Authors: Robert J. Motzer, Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R. Plimack, Philippe Barthélémy, Hans J. Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K. Choueiri, Brian I. Rini, Pamela Salman, Christian Kollmannsberger, Scott S. Tykodi, Marc‐Oliver Grimm, Howard Gurney, Raya Leibowitz‐Amit, Poul Geertsen, Asim Amin, Yoshihiko Tomita, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Journal for ImmunoTherapy of Cancer 2020 cited by 225

  22. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    Authors: Bernard Escudier, A Płużańska, P. Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, Emilio Bajetta, В. А. Горбунова, Jacques‐Olivier Bay, I. Bodrogi, Agnieszka Jagiełło-Gruszfeld, N. Moore - The Lancet 2007 cited by 2,223

  23. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial

    Authors: Michiel S. van der Heijden, Yohann Loriot, Ignacio Durán, Alain Ravaud, Margitta Retz, Nicholas J. Vogelzang, B. Nelson, Jingjing Wang, Xiaodong Shen, Thomas Powles - European Urology 2021 cited by 121

  24. Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review

    Authors: Mathieu Larroquette, Charlotte Domblides, Félix Lefort, M Lasserre, Amandine Quivy, Baptiste Sionneau, Pauline Bertolaso, Marine Gross‐Goupil, Alain Ravaud, Amaury Daste - European Journal of Cancer 2021 cited by 76